Last updated: April 29, 2026
AU2014345507: Scope, Claims, and Australian Patent Landscape Analysis
What does AU2014345507 cover?
AU2014345507 is an Australian patent application published as AU2014345507 (priority from a related international filing). The document sits in the core “composition and use” space typical of follow-on portfolios, where claim breadth is driven by (i) defined chemical entities and salts, (ii) formulation parameters (if present), and (iii) method-of-treatment and patient/indication language.
However, the full scope and claim set cannot be reproduced accurately from the information provided in this request alone. A correct claim chart requires the exact claim text (all independent and dependent claims), the specification’s definitions (active ingredient scope, ranges, embodiments), and the prosecution outcomes (grants, amendments, oppositions, and any terminal disclaimers or limiting construction from the Australian Patent Office).
Because those inputs are not present here, generating a definitive scope-and-claims analysis would be incomplete.
What are the independent claim boundaries (composition vs method-of-use)?
A complete “scope map” for AU2014345507 requires:
-
The exact independent claim(s) and their construction drivers:
- Defined active(s): compound structure, generic class language, stereochemistry, salt/hydrate inclusion.
- Formulation limits: dosage form, excipients, particle size, pH, release profile.
- Use language: indication, patient subset, line of therapy, biomarker status, dosing regimen.
-
The dependent claim cascade that typically narrows scope using:
- Specific salts/hydrates.
- Specific dosage strengths or regimens.
- Specific patient populations and criteria.
- Specific combination partners and sequence.
-
Any process claims (if present), including preparation steps or intermediates that can drive freedom-to-operate risk via manufacturing route.
Without the claim text, no reliable delineation of independent boundaries can be produced.
What does claim dependency imply for enforceability in Australia?
For Australian drug patents, enforceability and practical scope depend on how claims are drafted and maintained through examination. AU2014345507’s enforceability hinges on:
- Whether novelty hinges on a defined chemical identity (narrower but easier to establish infringement by product match).
- Whether novelty hinges on use or regimen language (often stronger against “same drug, different use” entrants, but narrower on proof).
- Whether dependent claims provide fallback positions (more claims surviving increases litigation leverage).
- Whether breadth is tied to Markush-style substitution language (which expands coverage but can increase validity challenge risk).
A credible analysis requires the actual dependent claim set and any limitations incorporated from the description into claim interpretation.
What is the likely patent landscape around AU2014345507?
A rigorous landscape for an Australian filing normally includes:
- Family members: EP/US/WO publications and their claim scopes, plus granted status by jurisdiction.
- Australian equivalents: any linked AU application filings in the same family (or continuation equivalents).
- Competing local filings:
- Same API with alternate salts, polymorphs, or formulations.
- Same indication with new biomarkers, dosing, or combinations.
- Combination patents that can dominate local use carve-outs.
- Regulatory linkage effects (where applicable):
- Whether the patent appears in Australian registration or is connected to medicine regulatory approval pathways.
These elements must be anchored to the actual subject matter of AU2014345507, which is not provided in the request. Without knowing the drug, target, or indication, landscape mapping cannot be completed correctly.
Evidence required to complete the analysis
A complete deliverable needs the following facts extracted from AU2014345507 and its family documents:
- Full claim text (all independent and dependent claims).
- Publication and priority dates.
- Applicant/assignee and prosecution status in Australia (filed, examined, granted, refused).
- Any amendments and final claim set at grant (critical for real enforceability).
- The specification’s definitions that constrain claim interpretation (active ingredient scope, formulation parameters, and embodiment definitions).
- Related publications in the same family for cross-jurisdictional claim comparison.
These inputs are not present.
Key Takeaways
- AU2014345507 scope and claim boundaries cannot be stated accurately without the patent’s claim text, definitions, and prosecution-grant status in Australia.
- A meaningful Australian landscape requires the drug/indication subject matter and the family’s granted claim set, not just the application number.
- Without those primary document extracts, any “detailed analysis” would risk inventing scope, which is not acceptable for an enforceability or freedom-to-operate decision.
FAQs
-
What determines whether AU2014345507 is enforceable against a generic entrant?
The exact independent claims (composition vs method-of-use), the final granted claim set, and how infringement is proven against product composition and/or prescribed use.
-
How does Australia treat dependent claims in infringement disputes?
Dependent claims narrow scope and can provide “fallback” coverage; infringement analysis often compares accused products or regimens against the specific claim limitations.
-
Why do formulation and dosing claims matter for AU drug patents?
They can separate “same active ingredient” products by release profile, salt form, regimen, or patient dosing, which changes both infringement and validity arguments.
-
How does family comparison affect an AU landscape view?
Claims in granted jurisdictions and amended versions often show which features survive validity challenges and thus tend to be the true leverage points in Australia.
-
What is the most common reason a landscape assessment fails for an AU application number?
Not extracting the actual claim text and final grant status, then mapping competitors to those exact limitations.
References
None.
